Vaxcyte, Inc.
PCVX
$30.65
$1.535.25%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | 226.16% |
| Gross Profit | -- | -- | -- | -- | -226.16% |
| SG&A Expenses | 62.93% | 47.31% | 48.55% | 51.65% | 46.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.55% | 23.80% | 75.54% | 60.79% | 127.18% |
| Operating Income | 17.55% | -23.80% | -75.54% | -60.79% | -127.18% |
| Income Before Tax | 24.18% | -11.29% | -88.33% | -57.16% | -131.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.18% | -11.29% | -88.33% | -57.16% | -131.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.18% | -11.29% | -88.33% | -57.16% | -131.65% |
| EBIT | 17.55% | -23.80% | -75.54% | -60.79% | -127.18% |
| EBITDA | 18.63% | -23.09% | -75.50% | -61.00% | -128.00% |
| EPS Basic | 42.50% | 8.53% | -57.50% | -21.29% | -78.52% |
| Normalized Basic EPS | 42.52% | 8.51% | -57.53% | -21.33% | -78.62% |
| EPS Diluted | 42.50% | 8.53% | -57.50% | -21.29% | -78.52% |
| Normalized Diluted EPS | 42.52% | 8.51% | -57.53% | -21.33% | -78.62% |
| Average Basic Shares Outstanding | 31.87% | 21.66% | 19.58% | 29.56% | 29.76% |
| Average Diluted Shares Outstanding | 31.87% | 21.66% | 19.58% | 29.56% | 29.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |